WO2004108756A3 - Peptides du coronavirus du sras et leurs applications - Google Patents

Peptides du coronavirus du sras et leurs applications Download PDF

Info

Publication number
WO2004108756A3
WO2004108756A3 PCT/CA2004/000856 CA2004000856W WO2004108756A3 WO 2004108756 A3 WO2004108756 A3 WO 2004108756A3 CA 2004000856 W CA2004000856 W CA 2004000856W WO 2004108756 A3 WO2004108756 A3 WO 2004108756A3
Authority
WO
WIPO (PCT)
Prior art keywords
sars
peptides
sars coronavirus
virus
causes
Prior art date
Application number
PCT/CA2004/000856
Other languages
English (en)
Other versions
WO2004108756A2 (fr
Inventor
William Campbell
William Jia
Qun Zhou
Original Assignee
Pegasus Pharmaceuticals Group
William Campbell
William Jia
Qun Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pegasus Pharmaceuticals Group, William Campbell, William Jia, Qun Zhou filed Critical Pegasus Pharmaceuticals Group
Publication of WO2004108756A2 publication Critical patent/WO2004108756A2/fr
Publication of WO2004108756A3 publication Critical patent/WO2004108756A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des peptides se liant aux anticorps codés par des parties du génome d'un virus causant le syndrome respiratoire aigu sévère (SRAS). L'invention concerne également l'utilisation de ces peptides et de réseaux comprenant ces peptides dans le diagnostic du SRAS, pour déterminer le stade d'une infection par le SRAS, ou pour identifier des individus qui ont été infectés par un virus causant le SRAS. Ces peptides peuvent également être utilisés dans la préparation de vaccins destinés au traitement ou à la prévention du SRAS.
PCT/CA2004/000856 2003-06-09 2004-06-09 Peptides du coronavirus du sras et leurs applications WO2004108756A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CA2431860 2003-06-09
CA2,431,860 2003-06-09
US32027203P 2003-06-13 2003-06-13
US60/320,272 2003-06-13
CA2432360 2003-07-10
CA2,432,360 2003-07-10
US52872103P 2003-12-12 2003-12-12
US60/528,721 2003-12-12

Publications (2)

Publication Number Publication Date
WO2004108756A2 WO2004108756A2 (fr) 2004-12-16
WO2004108756A3 true WO2004108756A3 (fr) 2005-06-09

Family

ID=33514752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2004/000856 WO2004108756A2 (fr) 2003-06-09 2004-06-09 Peptides du coronavirus du sras et leurs applications

Country Status (1)

Country Link
WO (1) WO2004108756A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022270624A1 (fr) * 2021-06-24 2022-12-29 良広 渡部 Polypeptide d'induction d'anticorps et vaccin

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BEIJING DA XUE XUE BAO. YI XUE BAN = JOURNAL OF PEKING UNIVERSITY. HEALTH SCIENCES. 31 MAY 2003, vol. 35 Suppl, 31 May 2003 (2003-05-31), pages 70 - 71, ISSN: 1671-167X *
CHE X-Y ET AL: "RAPID AND EFFICIENT PREPARATION OF MONOCLONAL ANTIBODIES AGAINST SARS-ASSOCIATED CORONAVIRUS NUCLEOCAPSID PROTEIN BY IMMUNIZING MICE", DI YI JUNYI DAXUE XUEBAO - ACADEMIC JOURNAL OF FIRST MEDICAL COLLEGE OF PLA, GAI KAN BIANJISHI, GUANGZHOU, CN, vol. 23, no. 7, July 2003 (2003-07-01), pages 640 - 642, XP008028243, ISSN: 1000-2588 *
DATABASE EMBL 15 April 2003 (2003-04-15), "SARS coronovirus Tor2, complete genome", XP002297844, Database accession no. AY274119 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 31 May 2003 (2003-05-31), WANG YUEDAN ET AL: "[Immunoinformatic analysis for the epitopes on SARS virus surface protein]", XP002297843, Database accession no. NLM12914223 *
IRVING MELITA B ET AL: "Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 5, no. 3, June 2001 (2001-06-01), pages 314 - 324, XP002297841, ISSN: 1367-5931 *
LIN YING ET AL: "Identification of an epitope of SARS-coronavirus nucleocapsid protein", CELL RESEARCH - XIBAO YANJIU, BEIJING, CN, vol. 13, no. 3, June 2003 (2003-06-01), pages 141 - 145, XP002272576, ISSN: 1001-0602 *
MARRA MARCO A ET AL: "The Genome sequence of the SARS-associated coronavirus", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1399 - 1404, XP002288939, ISSN: 0036-8075 *
NAVAS-MARTÍN SONIA R ET AL: "Coronavirus replication and pathogenesis: Implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development.", JOURNAL OF NEUROVIROLOGY. APR 2004, vol. 10, no. 2, April 2004 (2004-04-01), pages 75 - 85, XP002297842, ISSN: 1355-0284 *

Also Published As

Publication number Publication date
WO2004108756A2 (fr) 2004-12-16

Similar Documents

Publication Publication Date Title
WO2021188969A3 (fr) Vaccins à coronavirus et procédés d'utilisation
WO2001068116A3 (fr) Prevention et traitement d'infections respiratoires virales au moyen de sequences polynucleotidiques immunomodulatoires
WO2001068117A3 (fr) Methodes permettant de reduire l'infection par papillomavirus au moyen de sequences polynucleotidiques imunomodulatoires
WO2007041487A3 (fr) Peptides inhibiteurs d'infections virales
WO2006044923A3 (fr) Moyens therapeutiques a base de levure contre l'infection par hepatite c chronique
WO2007057763A3 (fr) Oxyde nitrique utilisé comme agent antiviral, vaccin et adjuvant de vaccin
WO2004060308A3 (fr) Thiosemicarbazones antiviraux et immunostimulants
WO2006110655A3 (fr) Composes, compositions et methodes de traitement des infections a poxvirus
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
WO2001068077A3 (fr) Prevention et traitement d'infections virales au moyen de sequences polynucleotidiques immunomodulatoires
WO2005023083A3 (fr) Compositions et procedes pour traiter le syndrome respiratoire aigu severe
HUP0400685A2 (hu) Módosított Vacciniavírus Ankara-variáns
WO2005023290A3 (fr) Utilisation d'interferons pour traiter le syndrome respiratoire aigu severe et d'autres infections virales
WO2006122819A8 (fr) Utilisation d'inhibiteurs de ras
EP2204179A3 (fr) Vaccin à base de virus modifié Ankara pour la vaccination de nouveaux-nés
WO2006077427A3 (fr) Combinaisons de medicaments antiviraux
WO2001055111A8 (fr) Composes biaryles, leur preparation et utilisation en therapie
AUPQ761200A0 (en) Compositions and methods for treatment of mucosal infections
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
WO2007057436A3 (fr) L’interferon dans la grippe
WO2006024240A3 (fr) Composition vaccinale contre le virus de l'hepatite c
AU2002225509A1 (en) Production and of viruses, viral isolates and vaccines
WO2008045017A3 (fr) Inhibiteurs des virus sars et ebola, leur utilisation, et procédés pour les découvrir
WO2005067906A3 (fr) Composition pharmaceutique
WO2004108756A3 (fr) Peptides du coronavirus du sras et leurs applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase